NCT04340557View on ClinicalTrials.gov

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 27, 2020

Primary Completion Date

June 13, 2020

Study Completion Date

June 13, 2020

Conditions
SARS-CoV Infection
Interventions
DRUG

Losartan

Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.

Trial Locations (3)

91911

Sharp Chula Vista Medical Center, San Diego

91942

Sharp Grossmont Hospital, La Mesa

92123

Sharp Memorial Hospital, San Diego

All Listed Sponsors
lead

Sharp HealthCare

OTHER

NCT04340557 - Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter